Zobrazeno 1 - 10
of 910
pro vyhledávání: '"Triptan"'
Autor:
Wen-Hui Liu, Hui-Min Hu, Chen Li, Qing Shi, Chun-Hua Liu, An-Xiang Liu, Yi-Fan Li, Yi Zhang, Peng Mao, Bi-Fa Fan
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-17 (2024)
Abstract Background Triptans selectively agoniste 5-Hydroxytryptamine(5-HT) receptors and are widely used in the treatment of migraine. Nevertheless, there is a dearth of comprehensive real-world clinical research on the safety of triptans. In light
Externí odkaz:
https://doaj.org/article/65851d866a4644209009a8dfc2df51ad
Autor:
Wattakorn Laohapiboolrattana, Priabprat Jansem, Prakit Anukoolwittaya, Duangnapa Roongpiboonsopit, Akarin Hiransuthikul, Thanakit Pongpitakmetha, Sekh Thanprasertsuk, Wanakorn Rattanawong
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-12 (2024)
Abstract Background Novel abortive treatments for migraine, ditans and gepants, have promising implications in triptan-insufficient responders with minimal existing comparative data. Our study aims to synthesize evidence through a systematic review a
Externí odkaz:
https://doaj.org/article/e3df1b39a46a4f10b7cf49a72612a3db
Publikováno v:
Neurology International, Vol 16, Iss 3, Pp 643-652 (2024)
The combined use of lasmiditan and triptan is unexplored in medical literature. This study aimed to investigate whether the intake of lasmiditan following triptan improves migraine pain. Following triptan intake, if headache relief was less than 50%
Externí odkaz:
https://doaj.org/article/e86ad86238c840d19810f1f7cd13856d
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background The objective of this study was to investigate the trends and prescribing patterns of antimigraine medicines in China. Methods The prescription data of outpatients diagnosed with migraine between 2018 and 2022 were extracted from
Externí odkaz:
https://doaj.org/article/ccbc7b44375e465c922de793b1082e6f
Autor:
Phuong Thao Tran, Maryse Lapeyre-Mestre, Baricault Berangere, Michel Lanteri-Minet, Aurore Palmaro, Anne Donnet, Joëlle Micallef
Publikováno v:
The Journal of Headache and Pain, Vol 25, Iss 1, Pp 1-12 (2024)
Abstract Background Several studies have focused on the use of triptan and the risk of acute vascular events but the existence of such association is still debated and has never been quantified in patients over 65 years. To assess whether triptan use
Externí odkaz:
https://doaj.org/article/a89630c1432543e4bcdad451bba73a89
Autor:
Ruth Ruscheweyh, Gudrun Gossrau, Thomas Dresler, Tobias Freilinger, Stefanie Förderreuther, Charly Gaul, Torsten Kraya, Lars Neeb, Victoria Ruschil, Andreas Straube, Jörg Scheidt, Tim Patrick Jürgens
Publikováno v:
The Journal of Headache and Pain, Vol 24, Iss 1, Pp 1-11 (2023)
Abstract Background Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or tolerability of ≥ 2
Externí odkaz:
https://doaj.org/article/29867564943648d7b1586e6eabe2c194
Publikováno v:
Molecules, Vol 29, Iss 17, p 4226 (2024)
This study aimed at the biotransformation of sumatriptan by Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa and Salmonella enterica subsp. enterica and the identification of the drug metabolites by liquid chromatography–mass spectr
Externí odkaz:
https://doaj.org/article/930bdb79c7b94457924169ef58a86b00
Autor:
Roland Houben
Publikováno v:
Journal of Medical Case Reports, Vol 17, Iss 1, Pp 1-4 (2023)
Abstract Background Severe acute respiratory syndrome coronavirus 2 is a virus affecting different organs and causing a wide variety and severity of symptoms. Headache as well as loss of smell and taste are the most frequently reported neurological m
Externí odkaz:
https://doaj.org/article/a60452bb96404521ba3eda4e5edef6e6
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Simona Sacco, Christian Lampl, Faisal Mohammad Amin, Mark Braschinsky, Christina Deligianni, Derya Uludüz, Jan Versijpt, Anne Ducros, Raquel Gil-Gouveia, Zaza Katsarava, Paolo Martelletti, Raffaele Ornello, Bianca Raffaelli, Deirdre M. Boucherie, Patricia Pozo-Rosich, Margarita Sanchez-del-Rio, Alexandra Sinclair, Antoinette Maassen van den Brink, Uwe Reuter
Publikováno v:
The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Triptans are migraine-specific acute treatments. A well-accepted definition of triptan failure is needed in clinical practice and for research. The primary aim of the present Consensus was to provide a definition of triptan failur
Externí odkaz:
https://doaj.org/article/f2e139c79f47462bb7a320e0480913ae